These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
409 related articles for article (PubMed ID: 2507171)
1. Inhibition of human NK cell and LAK cell cytotoxicity and differentiation by PGE2. Leung KH Cell Immunol; 1989 Oct; 123(2):384-95. PubMed ID: 2507171 [TBL] [Abstract][Full Text] [Related]
2. Elevated prostaglandin E2 production by monocytes is responsible for the depressed levels of natural killer and lymphokine-activated killer cell function in patients with breast cancer. Baxevanis CN; Reclos GJ; Gritzapis AD; Dedousis GV; Missitzis I; Papamichail M Cancer; 1993 Jul; 72(2):491-501. PubMed ID: 8319179 [TBL] [Abstract][Full Text] [Related]
3. In vivo boosting of lung natural killer and lymphokine-activated killer cell activity by interleukin-2: comparison of systemic, intrapleural and inhalation routes. Flexman JP; Manning LS; Robinson BW Clin Exp Immunol; 1990 Oct; 82(1):151-6. PubMed ID: 2208789 [TBL] [Abstract][Full Text] [Related]
4. Natural killer and lymphokine-activated killer cell activities from human marrow precursors. II. The effects of IL-3 and IL-4. Keever CA; Pekle K; Gazzola MV; Collins NH; Bourhis JH; Gillio A J Immunol; 1989 Nov; 143(10):3241-9. PubMed ID: 2809200 [TBL] [Abstract][Full Text] [Related]
5. PGE2, but not TGF beta 2, in rabbit blastocoelic fluid regulates the cytotoxic activities of NK and LAK cells. Bergeron D; Ouellette MJ; Lambert RD J Reprod Immunol; 1997 Jul; 33(3):203-19. PubMed ID: 9255724 [TBL] [Abstract][Full Text] [Related]
6. Differential modulation of LAK and ADCC functions of natural killer cells from AK-5 tumor-bearing rats by IL-2, IL-12 and IFN-gamma. Muralikrishna K; Varalakshmi C; Khar A Cytokines Cell Mol Ther; 1997 Mar; 3(1):51-8. PubMed ID: 9287244 [TBL] [Abstract][Full Text] [Related]
7. Intracellular calcium changes associated with in vitro lymphokine-activated killer and natural killer cell cytotoxicity. Burkey BB; Omann GM; Wolf GT Arch Otolaryngol Head Neck Surg; 1991 Nov; 117(11):1281-6. PubMed ID: 1747234 [TBL] [Abstract][Full Text] [Related]
8. Target cell-directed inactivation and IL-2-dependent reactivation of LAK cells. Xiao J; Brahmi Z Cell Immunol; 1989 Sep; 122(2):295-306. PubMed ID: 2788512 [TBL] [Abstract][Full Text] [Related]
9. Induction of human lymphokine-activated killer cells by IFN-alpha and IFN-gamma. Ellis TM; McKenzie RS; Simms PE; Helfrich BA; Fisher RI J Immunol; 1989 Dec; 143(12):4282-6. PubMed ID: 2512355 [TBL] [Abstract][Full Text] [Related]
10. Prostaglandin E2-mediated inactivation of various killer lineage cells by tumor-bearing host macrophages. Parhar RS; Lala PK J Leukoc Biol; 1988 Dec; 44(6):474-84. PubMed ID: 2973508 [TBL] [Abstract][Full Text] [Related]
11. The relative resistance of lymphokine activated killer cells to suppression by prostaglandins and glucocorticoids. Imir T; Sibbitt W; Bankhurst A Prostaglandins Leukot Med; 1987 Jul; 28(2):111-8. PubMed ID: 3498171 [TBL] [Abstract][Full Text] [Related]
12. Interferon-gamma-treated K562 target cells distinguish functional NK cells from lymphokine-activated killer (LAK) cells. Powell J; Stone J; Chan WC; Yang ZD; Leatherbury A; Sell KW; Wiktor-Jedrzejczak W; Ahmed-Ansari A Cell Immunol; 1989 Feb; 118(2):250-64. PubMed ID: 2491960 [TBL] [Abstract][Full Text] [Related]
13. Human lymphokine-activated killer (LAK) cells: III. Effect of L-phenylalanine methyl ester on LAK cell activation from human peripheral blood mononuclear cells: possible protease involvement of monocytes, natural killer cells and LAK cells. Leung KH Cancer Immunol Immunother; 1991; 34(1):31-6. PubMed ID: 1760808 [TBL] [Abstract][Full Text] [Related]
14. Effects of recombinant interferon-gamma and interleukin-2 on the generation of lymphokine-activated killer cells in vitro. Findley HW; Nasr S; Afify Z; Hnath R; Waldrep K; Ragab AH Cancer Invest; 1990; 8(5):493-500. PubMed ID: 2124946 [TBL] [Abstract][Full Text] [Related]
15. Synergistic action of a plant rhamnogalacturonan enhancing antitumor cytotoxicity of human natural killer and lymphokine-activated killer cells: chemical specificity of target cell recognition. Mueller EA; Anderer FA Cancer Res; 1990 Jun; 50(12):3646-51. PubMed ID: 1692765 [TBL] [Abstract][Full Text] [Related]
16. Autologous bone marrow purging by in situ IL-2 activation of endogenous killer cells. Margolin KA; Wright C; Forman SJ Leukemia; 1997 May; 11(5):723-8. PubMed ID: 9180298 [TBL] [Abstract][Full Text] [Related]
17. Independent and synergistic effect of interleukin-2 and prolactin on development of T- and NK-derived LAK effectors. Cesano A; Oberholtzer E; Contarini M; Geuna M; Bellone G; Matera L Immunopharmacology; 1994; 28(1):67-75. PubMed ID: 7928303 [TBL] [Abstract][Full Text] [Related]
18. Effect of ASTA-Z 7575 (INN Maphosphamide) on human lymphokine-activated killer cell induction. Singh KP; Gupta RK; Shau H; Ray PK Immunopharmacol Immunotoxicol; 1993 Nov; 15(5):525-38. PubMed ID: 8301017 [TBL] [Abstract][Full Text] [Related]
19. Leukoregulin up-regulation of tumor cell sensitivity to natural killer and lymphokine-activated killer cell cytotoxicity. Furbert-Harris PM; Evans CH Cancer Immunol Immunother; 1989; 30(2):86-91. PubMed ID: 2688871 [TBL] [Abstract][Full Text] [Related]
20. Isolation of human NK cells and generation of LAK activity. Whiteside TL Curr Protoc Immunol; 2001 May; Chapter 7():Unit 7.7. PubMed ID: 18432847 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]